TrialNet's "Pathway to Prevention" Screens 100,000 Type 1 Relatives; Two New Prevention Trials in Progress

The national research program called Type 1 Diabetes TrialNet recently screened their 100,000th family member for autoantibodies as part of the Natural History Study, now known as the Pathway to Prevention. UCSF is proud to have been selected as one of the first TrialNet Clinical Centers just over a decade ago. For relatives of people with type 1 diabetes who are not yet diagnosed -- but who are at risk for type 1 diabetes -- there are now promising clinical trials available.

For those found to be at intermediate risk of developing diabetes (25 percent chance of getting diabetes in the next five years), there is a trial introducing oral insulin. For those found to be at high risk (greater than 50 percent chance of diabetes in the next five years), there is a trial utilizing the anti-CD3 monoclonal antibody. 

For more information on these studies or other clinical research being conducted at UCSF, contact Kathleen Fraser.